From: Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
OR | 95% CI | p value | OR | 95% CI | p value | |
Sex (male vs. female) | 4.9 | 0.79–30.3 | 0.09 | 2.7 | 0.31–22.7 | 0.37 |
Age at disease onset (≥ 40 vs. < 40 years old) | 2.0 | 0.38–10.5 | 0.41 | 1.9 | 0.20–17.5 | 0.59 |
Disease duration before anti-TNFα agent initiation (≥ 5 vs. < 5 years) | 0.4 | 0.07–2.7 | 0.38 | 0.4 | 0.04–4.96 | 0.49 |
Type of anti-TNFα agent administered (IFX vs. ADA) | 0.8 | 0.15–3.8 | 0.73 | |||
CRP level at baseline (≥ 1 vs. < 1 mg/dL) | 9.6 | 1.45–63.5 | 0.019 | 10.5 | 1.21–90.2 | 0.033 |
Concomitant use of systemic corticosteroid (≥ 20 mg) (yes vs. no) | 1.5 | 0.27–8.3 | 0.64 |